Literature DB >> 2901085

Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia.

D E Casey1, G A Keepers.   

Abstract

The neuroleptic-induced motor system side effects of acute extrapyramidal syndromes (EPS) and tardive dyskinesia (TD) are the major limitations of these drugs. Effective strategies for managing these problems are based on the clinical presentations, pathophysiological processes, and a complex interaction of patient and treatment variables. New concepts about the causes and long-term outcome of acute EPS and TD are emerging to challenge some of the commonly held views about these syndromes. The primary method of preventing undue side effects is to use the lowest effective dose of both neuroleptic and anti-EPS drugs. The pressing need is for novel compounds which treat schizophrenia and are free of the undesirable motor system effects (a nonneuroleptic neuroleptic).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901085     DOI: 10.1007/978-3-642-73280-5_7

Source DB:  PubMed          Journal:  Psychopharmacol Ser        ISSN: 0931-6795


  12 in total

Review 1.  Neuroleptic-induced dysphagia: case report and literature review.

Authors:  Rainer Dziewas; Tobias Warnecke; Martina Schnabel; Martin Ritter; Darius G Nabavi; Matthias Schilling; E Bernd Ringelstein; Thomas Reker
Journal:  Dysphagia       Date:  2006-10-06       Impact factor: 3.438

Review 2.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

3.  Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.

Authors:  H Lublin; J Gerlach; F Mørkeberg
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

4.  Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

Authors:  P E Holtom; P L Needham; G W Bennett; S Aspley
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

5.  Rapid tranquillisation in psychiatric emergency settings in Brazil: pragmatic randomised controlled trial of intramuscular haloperidol versus intramuscular haloperidol plus promethazine.

Authors:  Gisele Huf; E S F Coutinho; C E Adams
Journal:  BMJ       Date:  2007-10-22

6.  A comparative study of neuroleptic induced neurological side effects in schizophrenia and mood disorders.

Authors:  P N Kumar; T M Kumar
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

7.  Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  The effects of D1 (NNC 22-0215) and D2 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 9.  Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.

Authors:  Rahn Kennedy Bailey
Journal:  J Natl Med Assoc       Date:  2003-02       Impact factor: 1.798

10.  Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates.

Authors:  D E Casey
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.